APYX - Apyx Medical Corporation
| Previous Close | 3.6700 |
| Open | 3.6800 |
| Bid | 3.8100 x 800 |
| Ask | 3.9000 x 1400 |
| Day's Range | 3.6800 - 3.9100 |
| 52 Week Range | 3.5500 - 8.8900 |
| Volume | 515,053 |
| Avg. Volume | 393,748 |
| Market Cap | 131.046M |
| Beta (3Y Monthly) | 0.50 |
| PE Ratio (TTM) | 2.00 |
| EPS (TTM) | 1.9290 |
| Earnings Date | May 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.25 |
-
GlobeNewswire • 2 minutes ago
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Apyx Medical Corporation To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Apyx Medical Corporation f/k/a Bovie Medical Corporation (“Apyx” or the “Company”) (APYX) of the June 17, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
-
GlobeNewswire • 7 hours ago
CLASS ACTION UPDATE for SPB, USX, CRBP and APYX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, April 19, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
-
Business Wire • 20 hours ago
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Apyx Medical Corporation and Encourages Investors to Contact the Firm Before June 17
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of Florida on behalf of those who acquired Apyx Medical Corporation (“Apyx” or the “Company”) (NASDAQ: APYX) securities during the period from August 1, 2018 through April 1, 2019 (the “Class Period”). Investors have until June 17, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
-
ACCESSWIRE • 21 hours ago
SHAREHOLDER ALERT: CTL WSR APYX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / April 18, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you ...
-
GlobeNewswire • 22 hours ago
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Apyx Medical Corporation (APYX)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Apyx Medical Corporation (“Apyx” or the “Company”) (APYX) in the United States District Court for the Middle District of Florida on behalf of those who purchased or acquired the securities of Apyx between August 1, 2018 and April 1, 2019, inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.
-
ACCESSWIRE • yesterday
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of INGN, CNDT and APYX
CEDARHURST, NY / ACCESSWIRE / April 18, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.
-
Business Wire • yesterday
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Apyx Medical Corporation Investors (APYX)
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Apyx Medical Corporation (“Apyx” or the “Company”) (NASDAQ: APYX) securities between August 1, 2018 and April 1, 2019, inclusive (the “Class Period”). Apyx investors have until June 17, 2019 to file a lead plaintiff motion. Investors suffering losses on their Apyx investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
-
GlobeNewswire • yesterday
Apyx Medical Corporation Shareholder Alert – Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of Apyx Medical Investors
PHILADELPHIA, April 18, 2019 -- Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of Apyx Medical Corporation (“Apyx”) (NASDAQ: APYX) pursuant to.
-
Business Wire • 2 days ago
Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Apyx Medical Corporation Investors (APYX)
Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Middle District of Florida, captioned Pritchard v. Apyx Medical Corporation et al., (Case No. 8:19-cv-00919), on behalf of persons and entities that purchased or otherwise acquired Apyx Medical Corporation (NASDAQ: APYX) (“Apyx” or the “Company”) securities between August 1, 2018, and April 1, 2019, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action.
-
Business Wire • 15 days ago
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Apyx Medical Corporation Investors (APYX)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Apyx Medical Corporation (“Apyx” or the “Company”) (NASDAQ: APYX) investors concerning the Company and its officers’ possible violations of federal securities laws. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On this news, shares of Apyx fell $2.49 per share, or over 35%, to close at $4.46 on April 2, 2019, thereby injuring investors.
-
Business Wire • 16 days ago
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Apyx Medical Corporation Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Apyx Medical Corporation investors (“Apyx” or the “Company”) (NASDAQ: APYX) concerning the Company and its officers’ possible violations of federal securities laws. On April 1, 2019, Apyx announced that it had withdrawn its 510(k) application for Renuvion, a patented surgical device for use in dermal surgical procedures, citing concerns raised by the FDA. Apyx revealed that the FDA had questioned the device’s clinical results, which differed greatly from two of the investigational centers used in the study, as well as the potential impact certain protocol deviations.
-
ACCESSWIRE • 16 days ago
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Apyx Medical Corporation (APYX) Investigation
NEW YORK, NY / ACCESSWIRE / April 3, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apyx Medical Corporation ("Apyx" or the "Company") ...
-
Motley Fool • 17 days ago
Why Apyx Medical's Stock Is Being Mauled Today
The share price was cut nearly in half after the company withdrew its FDA application for a new medical device
-
MarketWatch • 17 days ago
Apyx Medical's stock plummets toward worst 1-day drop in 19 years after withdrawing regulatory clearance application
Shares of Apyx Medical Corp. plummeted 37% toward 9-month low in morning trade Tuesday, after the company formerly known as Bovie Medical Corp. said it was withdrawing its application for regulatory clearance of its J-Plasma/Renuvion for use in dermal resurfacing procedures. The stock, which was pacing all decliners on the Nasdaq exchange, and was on track for the biggest one-day drop since January 2000. The company said late Monday that the withdrawal of its application for premarket notification 510(k) was voluntary, and followed an investigational device exemption study that failed to meet the primary efficacy endpoint. The company said it cannot provide a timeline for re-submission, but said it plans to do so after further discussions with the Food and Drug Administration. The stock has now low 33% year to date, but was still up 49% over the past 12 months. In comparison, the S&P 500 has gained 11% over the past year.
-
Benzinga • 17 days ago
The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
-
Business Wire • 18 days ago
Apyx Medical Corporation Provides Update on the Premarket Notification 510(k) Submission to the U.S. Food and Drug Administration (FDA) for Use in Dermal Resurfacing Procedures
Apyx Medical Corporation, formerly known as Bovie Medical Corporation, (APYX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced it has voluntarily withdrawn its application for premarket notification 510(k) regulatory clearance of J-Plasma/Renuvion for use in dermal resurfacing procedures. The Company will continue to work with the U.S. Food and Drug Administration (the “Agency”) relative to the development of a new 510(k) submission. At the present time, the Company cannot provide a timeline for resubmission but intends to do so after further discussions with the Agency.
-
Business Wire • 18 days ago
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2019 Financial Results on May 8, 2019
Apyx Medical Corporation, formerly Bovie Medical Corporation, (APYX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced that financial results for the first quarter of fiscal year 2019 will be released after the market closes on Wednesday, May 8. To listen to the call by phone, interested parties may dial 844-507-6493 (or 647-253-8641 for international callers) and provide access code 8252538. Participants should ask for the Apyx Medical Corporation Call.
-
Zacks • 21 days ago
Apyx Medical (APYX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Apyx Medical (APYX) closed at $6.31, marking a -0.63% move from the previous day.
-
Zacks • last month
NASDAQ, S&P Recover Last Week’s Losses... and Then Some!
NASDAQ, S&P; Recover Last Week’s Losses... and Then Some!
-
Simply Wall St. • last month
What Type Of Shareholder Owns Apyx Medical Corporation’s (NASDAQ:APYX)?
A look at the shareholders of Apyx Medical Corporation (NASDAQ:APYX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect toRead More...
-
Motley Fool • last monthBovie Medical Corp (BVX) Q4 2018 Earnings Conference Call Transcript
BVX earnings call for the period ending December 31, 2018.
-
Associated Press • last month
Apyx: 4Q Earnings Snapshot
The Clearwater, Florida-based company said it had a loss of 12 cents per share. Losses, adjusted to account for discontinued operations, were 10 cents per share. The medical device maker posted revenue ...
-
Zacks • last month
Apyx Medical (APYX) Reports Q4 Loss, Lags Revenue Estimates
Apyx (APYX) delivered earnings and revenue surprises of 0.00% and -1.07%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
-
Business Wire • last month
Apyx Medical Corporation Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Introduces Fiscal Year 2019 Outlook
Advanced Energy Sales increase 40% year-over-year in Q4 and increase 71% year-over-year in FY’18
